Search

Search Constraints

You searched for: Author/Creator Rowe, Paul J

Search Results

1. 166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE. (11th October 2021)

2. 230. ENDOSCOPIC REFERENCE SCORE REMODELING SUBSCORE AND ESOPHAGEAL EOSINOPHIL COUNT DO NOT CORRELATE IN PLACEBO-TREATED EOSINOPHILIC ESOPHAGITIS PATIENTS FROM DUPILUMAB STUDIES. (24th September 2022)

3. 233. ENDOSCOPIC REFERENCE SCORE AND HISTOLOGICAL SCORING SYSTEM ARE COMPLEMENTARY ASSESSMENTS FOR CHARACTERIZING FIBROSTENOTIC OR INFLAMMATORY PHENOTYPES IN EOSINOPHILIC ESOPHAGITIS PATIENTS. (24th September 2022)

4. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Issue 10 (October 2021)

5. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Issue 1 (January 2022)